Clinical pharmacokinetics of simotinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC patients.

被引：1
|
作者：
Han, Xiaohong
Li, Ning
Hu, Xingsheng
Song, Yuanyuan
Zhang, Yan
Shi, Yuankai
机构：
[1] Chinese Acad Med Sci, Canc Inst Hosp, Dept Med Oncol, Beijing 100730, Peoples R China
[2] Peking Union Med Coll, Beijing 100021, Peoples R China
[3] Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Canc Inst Hosp, Beijing 100730, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e13575
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13575
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
    Su-Hee Cho
    Lee Chun Park
    Jun Ho Ji
    Silvia Park
    Deok Won Hwang
    Ji Yean Lee
    Yoon-La Choi
    Jung-Ho Han
    Jong-Mu Sun
    Jin Seok Ahn
    Keunchil Park
    Myung-Ju Ahn
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 315 - 320
  • [22] Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series
    Le, Xiuning
    Eisert, Anna
    Hsia, Te-Chun
    Raut, Nirmal Vivek
    Ahmad, Azura
    Chan, Oscar Siu Hong
    De Bondt, Charlotte
    Farrugia, David
    Froesch, Patrizia
    Gonzalez-Cao, Maria
    Hendriks, Lizza
    Hochmair, Maximilian J.
    Mazieres, Julien
    O'Sullivan, Hazel
    Samol, Jens
    van der Wekken, Anthonie J.
    Yang, Tsung-Ying
    Joshi, Kirti
    Vlassak, Soetkin
    Chang, Gee-Chen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Lam, Wei-Sen
    Le, Xiuning
    Eisert, Anna
    Himpe, Ulrike
    De Bondt, Charlotte
    Mazieres, Julien
    Petrini, Iacopo
    Tho, Lye Mun
    Ahmad, Azura
    Chik, Yin Kwan Jeannie
    Chung, Wai
    Lee, Kirsty
    Yang, Tsung-Ying
    Hsia, Te-Chun
    Joshi, Kirti
    Young, Louise
    Berghoff, Karin
    Vlassak, Soetkin
    Karachaliou, Niki
    van der Wekken, Anthonie
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 83 - 84
  • [24] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Ahmad, A. R.
    Tho, L. M.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T-Y.
    Le, X.
    Eisert, A. K.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Lam, W-S.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    Van der Wekken, A. J.
    Hsia, T-C.
    ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1584
  • [25] Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
    Le, X.
    Eisert, A.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Tho, L. M.
    Ahmad, A.
    Lam, W. -S.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T. -Y.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    v. d. Wekken, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S483 - S484
  • [26] EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors
    Barnet, Megan B.
    O'Toole, Sandra
    Horvath, Lisa G.
    Selinger, Christina
    Yu, Bing
    Ng, Chiu Chin
    Boyer, Michael
    Cooper, Wendy A.
    Kao, Steven
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (03) : 585 - 590
  • [27] CLINICAL IMPLICATIONS OF RE-BIOPSY IN PATIENTS WITH NSCLC HARBOURING EGFR MUTATIONS WITH ACQUIRED RESISTANCE TO EGFR TYROSINE KINASE INHIBITORS
    Passaro, A.
    Gori, B.
    Leone, A.
    Graziano, P.
    de Marinis, F.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S19 - S19
  • [28] Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
    Sun, Yongkun
    Niu, Wei
    Du, Feng
    Du, Chunxia
    Li, Shuting
    Wang, Jinwan
    Li, Li
    Wang, Fengqing
    Hao, Yu
    Li, Chuan
    Chi, Yihebali
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9 : 1 - 9
  • [29] Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
    Yongkun Sun
    Wei Niu
    Feng Du
    Chunxia Du
    Shuting Li
    Jinwan Wang
    Li Li
    Fengqing Wang
    Yu Hao
    Chuan Li
    Yihebali Chi
    Journal of Hematology & Oncology, 9
  • [30] EGFR mutations in patients with advanced NSCLC
    Fiala, Ondrej
    Pesek, Milos
    Finek, Jindrich
    Bruha, Frantisek
    Bortlicek, Zbynek
    Krejci, Jana
    Benesova, Lucie
    Minarik, Marek
    LUNG CANCER, 2012, 77 : S30 - S30
12345